Vitamin D Receptor Agonists for Patients Undergoing Hemodialysis

Cardiovascular disease (CVD) is the leading cause of death among patients with end-stage kidney disease (ESKD) who are undergoing hemodialysis, yet many standard cardioprotective therapies have not been effective in reducing CVD in this patient population.' This reality has motivated the quest...

Full description

Saved in:
Bibliographic Details
Published in:JAMA : the journal of the American Medical Association 2018-12, Vol.320 (22), p.2319-2321
Main Authors: Hall, Rasheeda K, Scialla, Julia J
Format: Article
Language:English
Subjects:
Cardiovascular disease
Cardiovascular diseases
Dialysis
End-stage renal disease
Enzymes
Hemodialysis
Hydroxylase
Kidney diseases
Kidneys
Patients
Vitamin D
Vitamin deficiency
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiovascular disease (CVD) is the leading cause of death among patients with end-stage kidney disease (ESKD) who are undergoing hemodialysis, yet many standard cardioprotective therapies have not been effective in reducing CVD in this patient population.' This reality has motivated the quest to identify dialysis-related and kidney disease-specific factors that promote CVD. Based on observations from the past 2 decades, deficiency of active vitamin D has been a prime candidate for CVD reduction. In patients with ESKD, activity of the 1-a-hydroxylase enzyme is substantially diminished. This enzyme is primarily expressed in the kidney and converts 25-hydroxyvitamin D to active 1,25 dihydroxyvitamin D (l,25[OH]2D).
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2018.17477